U.S. Markets closed
  • S&P 500

    4,173.85
    +61.35 (+1.49%)
     
  • Dow 30

    34,382.13
    +360.68 (+1.06%)
     
  • Nasdaq

    13,429.98
    +304.99 (+2.32%)
     
  • Russell 2000

    2,132.86
    -74.13 (-3.36%)
     
  • Crude Oil

    63.78
    -2.30 (-3.48%)
     
  • Gold

    1,827.90
    +5.10 (+0.28%)
     
  • Silver

    27.10
    -0.56 (-2.03%)
     
  • EUR/USD

    1.2080
    -0.0072 (-0.5919%)
     
  • 10-Yr Bond

    1.6350
    -0.0330 (-1.98%)
     
  • Vix

    28.25
    +6.41 (+29.35%)
     
  • GBP/USD

    1.4057
    -0.0087 (-0.6171%)
     
  • USD/JPY

    109.6200
    +1.0000 (+0.9206%)
     
  • BTC-USD

    49,206.84
    -96.30 (-0.20%)
     
  • CMC Crypto 200

    1,377.31
    +18.75 (+1.38%)
     
  • FTSE 100

    7,004.63
    +56.64 (+0.82%)
     
  • Nikkei 225

    28,147.51
    -461.08 (-1.61%)
     

UPDATE 2-China likely to approve BioNTech's COVID-19 vaccine by July - WSJ

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

(Adds BioNTech's response, share movement)

April 16 (Reuters) - China is planning to authorize the COVID-19 vaccine developed by Germany's BioNTech SE by July, the Wall Street Journal reported on Friday, citing people familiar with the matter.

If approved, it would become the first foreign COVID-19 vaccine to be authorized in the country.

Chinese officials are reviewing clinical-trial data for the vaccine and are expected to authorize it for domestic use within the next 10 weeks, the report said.

BioNTech said in a statement that it does not speculate on timings of approvals.

The National Health Commission of China and Shanghai Fosun Pharmaceutical Group Co Ltd, which signed a potential supply deal with the German drugmaker in August for the vaccine, did not immediately respond to Reuters requests for comment. (https://reut.rs/2Q8psHJ)

The vaccine, developed in collaboration with Pfizer Inc , is already approved in several countries, including the United States, the United Kingdom and Israel.

U.S.-listed shares of BioNTech were up 3.3% at $145.4 on Friday.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Aditya Soni)